{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:33:22Z","timestamp":1791048802294,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ejps.2010.01.001","type":"journal-article","created":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T11:03:35Z","timestamp":1264071815000},"page":"336-347","source":"Crossref","is-referenced-by-count":48,"title":["In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution"],"prefix":"10.1016","volume":"39","author":[{"given":"Wei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keat Theng","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith P.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert O.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2010.01.001_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jpba.2008.10.032","article-title":"Physicochemical properties of antifungal drug\u2013cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques","volume":"49","author":"Al-Marzouqi","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2010.01.001_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jps.20535","article-title":"Phase solubility and inclusion complex of itraconazole with beta-cyclodextrin using supercritical carbon dioxide","volume":"95","author":"Al-Marzouqi","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinf.2007.01.014","article-title":"Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis","volume":"55","author":"Alvarez","year":"2007","journal-title":"J. Infect."},{"key":"10.1016\/j.ejps.2010.01.001_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male-volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/28.4.555","article-title":"Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia","volume":"28","author":"Bradford","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejps.2010.01.001_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10847-006-9249-0","article-title":"Solubilization of itraconazole as a function of cyclodextrin structural space","volume":"57","author":"Brewster","year":"2007","journal-title":"J. Inclusion Phenom. Macrocyclic Chem."},{"key":"10.1016\/j.ejps.2010.01.001_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijpharm.2007.04.029","article-title":"Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins","volume":"342","author":"Brewster","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib9","first-page":"231","article-title":"The potential use of cyclodextrins in parenteral formulations","volume":"43","author":"Brewster","year":"1989","journal-title":"J. Parenter. Sci. Technol."},{"key":"10.1016\/j.ejps.2010.01.001_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2008.02.007","article-title":"Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions","volume":"34","author":"Brewster","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib11","series-title":"Respiratory Drug Delivery","article-title":"Absorption, clearance and dissolution in the lung","author":"Byron","year":"1990"},{"key":"10.1016\/j.ejps.2010.01.001_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jam.1994.7.49","article-title":"Drug delivery via the respiratory tract","volume":"7","author":"Byron","year":"1994","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.ejps.2010.01.001_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00001432-200212000-00003","article-title":"Recent trends in the epidemiology of invasive mycoses","volume":"15","author":"Clark","year":"2002","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.ejps.2010.01.001_bib14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ejpb.2008.05.026","article-title":"Surface composition and contact angle relationships for differently prepared solid dispersions","volume":"70","author":"Dahlberg","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","article-title":"Pharmacology of itraconazole","volume":"61","author":"De Beule","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2010.01.001_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0928-0987(99)00081-0","article-title":"Complexation of the interferon inducer, bropirimine, with hydroxypropyl-beta-cyclodextrin","volume":"9","author":"Echezarreta-Lopez","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1021\/bk-2006-0924.ch019","article-title":"Particle engineering of poorly water soluble drugs by controlled precipitation","volume":"924","author":"Elder","year":"2006","journal-title":"ACS Symp. Ser."},{"key":"10.1016\/j.ejps.2010.01.001_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejpb.2005.02.010","article-title":"Human respiratory epithelial cell culture for drug delivery applications","volume":"60","author":"Forbes","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0034-5687(71)90009-0","article-title":"Morphometric estimation of pulmonary diffusion capacity. 3. The effect of increased oxygen consumption in Japanese Waltzing mice","volume":"11","author":"Geelhaar","year":"1971","journal-title":"Resp. Physiol."},{"key":"10.1016\/j.ejps.2010.01.001_bib20","doi-asserted-by":"crossref","first-page":"L1277","DOI":"10.1152\/ajplung.00128.2003","article-title":"Surface-lining layer of airways in cystic fibrosis mice","volume":"285","author":"Geiser","year":"2003","journal-title":"Am. J. Physiol.-Lung C"},{"key":"10.1016\/j.ejps.2010.01.001_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/(SICI)1097-0029(19970301)36:5<428::AID-JEMT13>3.0.CO;2-U","article-title":"Ultrastructure of the aqueous lining layer in hamster airways: is there a two-phase system?","volume":"36","author":"Geiser","year":"1997","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.ejps.2010.01.001_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0925-4439(98)00060-X","article-title":"Pulmonary surfactant: functions and molecular composition","volume":"1408","author":"Goerke","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2010.01.001_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole \u2013 an overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"10.1016\/j.ejps.2010.01.001_bib24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/AAC.50.4.1552-1554.2006","article-title":"In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis","volume":"50","author":"Hoeben","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2005.10.002","article-title":"A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption","volume":"110","author":"Hong","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2010.01.001_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/AAC.36.2.477","article-title":"Effect of cyclodextrin on the pharmacology of antifungal oral azoles","volume":"36","author":"Hostetler","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jac\/32.3.459","article-title":"Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis","volume":"32","author":"Hostetler","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","article-title":"Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation","volume":"86","author":"Irie","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1014276917363","article-title":"Production and characterization of a budesonide nanosuspension for pulmonary administration","volume":"19","author":"Jacobs","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0378-5173(87)90159-1","article-title":"The acetotoluides as models for studying cyclodextrin inclusion complexes","volume":"36","author":"Jones","year":"1987","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0169-409X(01)00115-6","article-title":"Drug transfer through mucus","volume":"48","author":"Khanvilkar","year":"2001","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.ejps.2010.01.001_bib32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1023\/B:PHAM.0000032997.96823.88","article-title":"Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes","volume":"21","author":"Koushik","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0091270003261490","article-title":"The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers","volume":"44","author":"Kraft","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2010.01.001_bib34","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0022-3565(24)37216-7","article-title":"Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells","volume":"284","author":"Lindmark","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2010.01.001_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1023\/A:1018934810512","article-title":"Pulmonary delivery of free and liposomal insulin","volume":"10","author":"Liu","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1773-2247(04)50003-5","article-title":"The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs","volume":"14","author":"Loftsson","year":"2004","journal-title":"J. Drug Deliv. Sci. Tech."},{"key":"10.1016\/j.ejps.2010.01.001_bib38","first-page":"237","article-title":"Methods to enhance the complexation efficiency of cyclodextrins","volume":"9","author":"Loftsson","year":"1999","journal-title":"STP Pharma Sci."},{"issue":"10","key":"10.1016\/j.ejps.2010.01.001_bib39","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/jps.20992","article-title":"Effects of cyclodextrins on drug delivery through biological membranes","volume":"96","author":"Loftsson","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5173(90)90132-N","article-title":"Studies of cyclodextrin inclusion complexes. 1. The salbutamol\u2013cyclodextrin complex as studied by phase solubility and DSC","volume":"63","author":"Marques","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0378-5173(91)90330-Q","article-title":"Studies of cyclodextrin inclusion complexes. 3. The pulmonary absorption of beta-cyclodextrin. Dm-beta-cyclodextrin and Hp-beta-cyclodextrin in rabbits","volume":"77","author":"Marques","year":"1991","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2010.01.001_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2007.11.003","article-title":"In vitro toxicity and permeation of cyclodextrins in Calu-3 cells","volume":"126","author":"Matilainen","year":"2008","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejps.2010.01.001_bib44","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/mp0700211","article-title":"Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media","volume":"4","author":"Matteucci","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11095-006-9904-6","article-title":"Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model","volume":"23","author":"McConville","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib46","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s11095-008-9543-1","article-title":"Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption","volume":"25","author":"Miller","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib47","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jps.20806","article-title":"Hot-melt extrusion for enhanced delivery of drug particles","volume":"96","author":"Miller","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0378-5173(98)00393-7","article-title":"Characterization of itraconazole\/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution","volume":"179","author":"Miyake","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future","volume":"47","author":"Muller","year":"2001","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejps.2010.01.001_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0731-7085(01)00414-9","article-title":"Formulation and evaluation of itraconazole via liquid crystal for topical delivery system","volume":"26","author":"Nesseem","year":"2001","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2010.01.001_bib51","series-title":"Pharmaceutical Inhalation Aerosol Technology","author":"Niven","year":"1992"},{"key":"10.1016\/j.ejps.2010.01.001_bib52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1023\/A:1018947113238","article-title":"Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans \u2013 a mathematical-model","volume":"10","author":"Oh","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0939-6411(99)00049-1","article-title":"An in-vitro assessment of a NanoCrystal (TM) beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization","volume":"48","author":"Ostrander","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/bdd.546","article-title":"In vitro and in vivo comparative study of itiraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion","volume":"28","author":"Park","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2010.01.001_bib55","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0140-6736(05)67381-3","article-title":"Advances and challenges in management of invasive mycoses","volume":"366","author":"Patterson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2010.01.001_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejps.2010.01.001_bib57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.ejps.2010.01.001_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev."},{"key":"10.1016\/j.ejps.2010.01.001_bib59","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the Interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib60","series-title":"Controlled Drug Delivery","article-title":"Molecular encapsulation of drugs by cyclodextrins and congeners","author":"Pitha","year":"1983"},{"key":"10.1016\/j.ejps.2010.01.001_bib61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","article-title":"Optimisation of itraconazole therapy using target drug concentrations","volume":"35","author":"Poirier","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2010.01.001_bib62","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/js960075u","article-title":"Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery","volume":"85","author":"Rajewski","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","volume":"24","author":"Rex","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2010.01.001_bib64","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1023\/A:1018997101542","article-title":"Cyclodextrins as mucosal absorption promoters of insulin. 2. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats","volume":"11","author":"Shao","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2010.01.001_bib65","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1139\/v05-181","article-title":"Enhancement of aqueous solubility of itraconazole by complexation with cyclodextrins using supercritical carbon dioxide","volume":"83","author":"Shehatta","year":"2005","journal-title":"Can. J. Chem."},{"key":"10.1016\/j.ejps.2010.01.001_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejps.2004.10.005","article-title":"Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion","volume":"24","author":"Six","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib67","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1086\/313746","article-title":"Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America","volume":"30","author":"Sobel","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2010.01.001_bib68","unstructured":"Sporanox\u00ae, p.l. Package insert. Sporanox capsules\/oral solution\/Sporanox I.V. (itraconazole)."},{"key":"10.1016\/j.ejps.2010.01.001_bib69","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejps.2010.01.001_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes","volume":"36","author":"Stella","year":"1999","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejps.2010.01.001_bib71","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.19.8.603.31529","article-title":"Itraconazole in cyclodextrin solution","volume":"19","author":"Stevens","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2010.01.001_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00762-06","article-title":"Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis","volume":"51","author":"Thiel","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2010.01.001_bib73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","article-title":"Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution","volume":"72","author":"Tolman","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib74","unstructured":"USP, 2008. Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhalers USP 31-NF 26. The United States Pharmacopeial Convention. Rockville, MD."},{"key":"10.1016\/j.ejps.2010.01.001_bib75","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1096","article-title":"Glucose, K+, and albumin concentrations in the alveolar milieu of normal humans and pulmonary sarcoidosis patients","volume":"143","author":"Valeyre","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejps.2010.01.001_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejpb.2005.01.002","article-title":"Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using novel Z-contrast STEM and complimentary techniques","volume":"60","author":"Vaughn","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2006.01.006","article-title":"Single dose and multiple dose studies of itraconazole nanoparticles","volume":"63","author":"Vaughn","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib78","first-page":"63","article-title":"Administration as hydroxypropyl-beta-cyclodextrin complexes does not slow rates of pulmonary drug absorption in rat","volume":"4","author":"Wall","year":"1994","journal-title":"STP Pharma Sci."},{"key":"10.1016\/j.ejps.2010.01.001_bib79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2010.01.001_bib80","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2008.02.011","article-title":"Inhaled nanoparticles \u2013 a current review","volume":"356","author":"Yang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib81","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.05.003","article-title":"High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers","volume":"361","author":"Yang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2010.01.001_bib82","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1517\/17425240802457188","article-title":"Drug delivery strategies for improved azole antifungal action","volume":"5","author":"Yang","year":"2008","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098710000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098710000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T22:20:33Z","timestamp":1739744433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098710000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0928098710000254"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2010.01.001","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}